11 July 2019 - The Trump administration on Wednesday abandoned one of its signature drug-pricing efforts: a ban on many of the rebates that drug companies pay to pharmacy benefit managers under Medicare.
A White House spokesman confirmed the news to STAT after it was first reported by Axios.
“Based on careful analysis and thorough consideration, the President has decided to withdraw the rebate rule,” spokesman Judd Deere said.